Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Low Level BCR-ABL1 G ene Fusion Detected By RT-PCR in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia Does Not Predict Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at Relapse: A 10-Year Single Institution Study

Lucy E Cain, BSc, MBBS, MPH, Oksana Mirochnik, Michael M Stevens, MBBS FRACP, Stewart J Kellie, MBBS FRACP MDMIntPH(Hons), Bhavna Padhye, MBBS FRACP MClinTRes PhD, Steven J Keogh, MBBS(Hons) FRACP, Dinisha Govender, MBChB FRACP, Jessica Ryan, BMed(Hons) FRACP, Luciano Dalla-Pozza, MBBS FRACP, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139359

Published: 2020

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Naomi Michels, BSc, Judith M. Boer, PhD, Marta Lopez-Yurda, PhD, Hester A. De Groot-Kruseman, PhD, Vincent van der Velden, PhD, Anthony V. Moorman, Amir Enshaei, PhD, Ajay Vora, Rosemary Sutton, BSc MSc PhD, Toby Trahair, PhD, Luciano Dalla-Pozza, MBBS FRACP, Rob Pieters, MDPhDMSc, Michel C Zwaan, MD PhD, Monique L. Den Boer, PhD

Blood (2019) 134 (Supplement_1): 827.

https://doi.org/10.1182/blood-2019-124290

Published: 2019

Journal Articles

High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL)

Alexander A Morley, MD, Sue Latham, BSc, Elizabeth Hughes, BSc, Bradley Budgen, BSc, Matthew Greenwood, FRACP, FRCPA, Kenneth F Bradstock, Luciano Dalla-Pozza, MBBS FRACP, Tamara Law, PhD, Louise Doculara, BSc, Nicola Venn, BSc, Rosemary Sutton, PhD

Blood (2018) 132 (Supplement 1): 2831.

https://doi.org/10.1182/blood-2018-99-110123

Published: 2018

Journal Articles

Clinical and Germline Risk Factors for the Occurrence of Multiple Treatment Toxicities during Childhood Acute Lymphoblastic Leukemia (ALL) Therapy

Marion K Mateos, MBBS FRACP, Toby N Trahair, MBBS FRACP PhD, Chelsea Mayoh, BSc, Pasquale M Barbaro, MBBS FRACP FRCPA, Carly George, MBBS, FRACP, Rosemary Sutton, PhD, Tamas Revesz, MDPhDD.Sc FRACP FRCPA, Draga Barbaric, MBBS FRACP, Jodie Giles, Frank Alvaro, FRACP, MBBS, Francoise Marie Mechinaud, MD FRACP, Daniel R Catchpoole, PhD BSc, Rishi Sury Kotecha, MBBChir, MRCP, FRACP, PhD, Michael CJ Quinn, BSc MSc PhD, Georgia Chenevix-Trench, BSc PhD, Stuart MacGregor, BSc MSc PhD, Luciano Dalla-Pozza, MBBS FRACP, Glenn M Marshall, MBBS, MD FRACP

Blood (2017) 130 (Supplement 1): 2102.

https://doi.org/10.1182/blood.V130.Suppl_1.2102.2102

Published: 2017

Journal Articles

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Blood (2015) 126 (23): 1419.

https://doi.org/10.1182/blood.V126.23.1419.1419

Published: 2015

Journal Articles

Improved Concordance of Minimal Residual Disease Measurements By Quantitative PCR and 10-Color Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia

Mary Sartor, PhD, Draga Barbaric, MBBS, Tamara Law, BSc (Hons), DR Anuruddhika Dissanayake, PhD, Nicola C Venn, Mawar Karsa, BSc (Hons), MSc, Sue W J Wong, BSc, MSc(MD, Murray D Norris, PhD, Tamas Revesz, MD PhD, Petra Ritchie, MBBS, Peter J Shaw, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, Luciano Dalla Pozza, MBBS, FRACP, Toby N Trahair, PhD MBBS, Rosemary Sutton, PhD

Blood (2015) 126 (23): 2614.

https://doi.org/10.1182/blood.V126.23.2614.2614

Published: 2015

Journal Articles

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Blood (2014) 124 (21): 795.

https://doi.org/10.1182/blood.V124.21.795.795

Published: 2014

NARROW

Low Level BCR-ABL1 G ene Fusion Detected By RT-PCR in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia Does Not Predict Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at Relapse: A 10-Year Single Institution Study

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL)

Clinical and Germline Risk Factors for the Occurrence of Multiple Treatment Toxicities during Childhood Acute Lymphoblastic Leukemia (ALL) Therapy

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Improved Concordance of Minimal Residual Disease Measurements By Quantitative PCR and 10-Color Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only